Chugai Pharmaceutical Co., Ltd.
Announcement of F. Hoffmann-La Roche Ltd.’s Fiscal 2025 Financial Results
F. Hoffmann-La Roche Ltd. announced its fiscal 2025 financial results. Chugai Pharmaceutical is a consolidated subsidiary of Roche Holdings, the parent company, holding 59.89% of issued shares as of the end of December 2025.
Key Figures
- Shareholding Ratio of Issued Shares: 59.89% (as of end of December 2025)
- Voting Rights Ratio: 61.12% (as of end of December 2025)
- Performance Period of Roche Group: January 1, 2025 to December 31, 2025
AI要約
Regarding F. Hoffmann-La Roche Ltd.'s Financial Results Announcement
F. Hoffmann-La Roche Ltd. (headquartered in Basel, Switzerland) has announced its fiscal 2025 financial results. Chugai Pharmaceutical is a subsidiary of Roche Holdings, which holds 59.89% of Chugai Pharmaceutical’s issued shares (voting rights ratio of 61.12%). The performance of the Roche Group includes Chugai Pharmaceutical’s results from January 1, 2025 to December 31, 2025.
Information for Investors and Future Reference
Detailed financial materials regarding this matter are available on the official Roche Group website (https://www.roche.com). Since the parent company's performance affects consolidated results, investors are advised to refer to the parent company’s financial information. Detailed standalone performance figures for Chugai Pharmaceutical are not included in this document.
